These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10064574)

  • 1. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
    Toda T; Eliasson E; Ask B; Inotsume N; Rane A
    Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C; Leemann T; Vogt N; Dayer P
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
    Kim KA; Park JY
    Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.
    Vickers AE; Sinclair JR; Zollinger M; Heitz F; Glänzel U; Johanson L; Fischer V
    Drug Metab Dispos; 1999 Sep; 27(9):1029-38. PubMed ID: 10460803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
    Filppula AM; Laitila J; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
    Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
    Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z; Soukhova N; Mahal SK; Flockhart DA
    Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
    Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
    Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
    J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
    Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N
    Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
    Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
    Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol.
    Franklin MR; Hathaway LB
    Drug Metab Dispos; 2008 Dec; 36(12):2539-46. PubMed ID: 18799803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.